<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00832130</url>
  </required_header>
  <id_info>
    <org_study_id>LF001</org_study_id>
    <nct_id>NCT00832130</nct_id>
  </id_info>
  <brief_title>Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye</brief_title>
  <official_title>Randomized Clinical Trial for Treatment of Meibomian Gland Dysfunction and Evaporative Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TearScience, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TearScience, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the clinical utility, safety and effectiveness of
      the Manual Mini System compared to standardized warm compress therapy for application of
      controlled, localized heat therapy in adult patients with chronic cystic conditions of the
      eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid
      deficiency dry eye, and chalazia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Meibomian Gland Assessment (Total Meibomian Gland Secretion Score)</measure>
    <time_frame>Baseline, 2 Weeks and 4 Weeks</time_frame>
    <description>Evaluation of secretion characteristics from the gland orifices along the lower eyelid. Assessment was based on the grading scale: 3 (clear liquid secretion), 2 (cloudy liquid secretion), 1 (inspissated), 0 (no secretion). The total meibomian gland secretion score was the sum of the grades for all 15 glands with a range of 0 to 45.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Device-related Adverse Events</measure>
    <time_frame>Baseline through 4 Weeks</time_frame>
    <description>Number of eyes for which a device-related AE occurred</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear Break-up Time</measure>
    <time_frame>Baseline, 2 Weeks and 4 Weeks</time_frame>
    <description>Tear break-up time measured under a slit lamp biomicroscope following instillation of fluorescein dye in the eye. Time was measured in seconds with a maximum of 20. Higher tear break-up time indicates better tear film stability.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dry Eye Symptoms (Total SPEED Score)</measure>
    <time_frame>Baseline, 2 Weeks and 4 Weeks</time_frame>
    <description>Standard Patient Evaluation of Eye Dryness questionnaire. Assessment of subjects' frequency and severity of dry eye symptoms. The total score was calculated as the sum scores for all symptoms over a range of 0 to 28. A lower total SPEED score represents less frequent and/or less severe symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Surface Staining (Corneal Staining Sum Score)</measure>
    <time_frame>Baseline through 4 Weeks</time_frame>
    <description>Corneal staining score in five corneal regions, evaluated on a scale from 0 (none), 1 (mild), 2 (moderate) to 3 (severe). The sum of the five corneal staining scores was on a scale from 0 to 15. A lower grade indicates less corneal surface desiccation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intraocular Pressure</measure>
    <time_frame>Baseline through 4 Weeks</time_frame>
    <description>Intraocular pressure (IOP) was evaluated by Goldmann applanation tonometry. Change in IOP from Baseline was assessed to confirm safety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(LogMAR) Best Spectacle Corrected Visual Acuity</measure>
    <time_frame>Baseline, 2 Weeks and 4 Weeks</time_frame>
    <description>Measurement of BSCVA at a distance using a logMAR chart under standard illumination. The logMAR ranged from -0.30 to 1.0. A lower logMAR value is a better visual acuity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discomfort Evaluation (Discomfort/Pain Score)</measure>
    <time_frame>Treatment and 1 Day</time_frame>
    <description>Subject-reported numeric score reflecting low or high intensity. Scores ranged from 0 to 10, with 0 being no discomfort or pain and 10 being intolerable pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">139</enrollment>
  <condition>Chalazion</condition>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Manual Mini System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with experimental Manual Mini System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Warm Compress Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Manual Mini System</intervention_name>
    <description>In-office device treatment for meibomian gland dysfunction by a physician</description>
    <arm_group_label>Manual Mini System</arm_group_label>
    <arm_group_label>Warm Compress Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iHeat Portable Warm Compress Therapy</intervention_name>
    <description>At-home daily warm compress therapy</description>
    <arm_group_label>Warm Compress Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age.

          -  Meibomian gland obstruction

          -  Dry eye symptoms

          -  Willingness to comply with study procedures and return for all visits

        Exclusion Criteria:

          -  Ocular surgery, injury, or herpes infection within past 3 months

          -  Active ocular infection

          -  Active ocular inflammation or recurrent inflammation within past 3 months

          -  Moderate to severe allergic conjunctivitis

          -  Severe eyelid inflammation

          -  Eyelid abnormalities that affect lid function

          -  Ocular surface abnormalities that may compromise corneal integrity

          -  Macular disease

          -  Systemic disease condition or medication that causes dry eye

          -  Use of other treatments for meibomian gland dysfunction or dry eye

          -  Pregnant or nursing women

          -  Participation in another ophthalmic clinical trial within past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christy Stevens, OD</last_name>
    <role>Study Director</role>
    <affiliation>TearScience, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morrow</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Highland Park</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Edgewood</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winchester</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jackson</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stillwater</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2009</study_first_submitted>
  <study_first_submitted_qc>January 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2009</study_first_posted>
  <results_first_submitted>September 19, 2011</results_first_submitted>
  <results_first_submitted_qc>November 1, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 6, 2011</results_first_posted>
  <last_update_submitted>December 5, 2011</last_update_submitted>
  <last_update_submitted_qc>December 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Chalazion</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 139 subjects (278 eyes) were enrolled at nine clinical sites between 03/04/2009 and 05/14/2009.</recruitment_details>
      <pre_assignment_details>At the 2 Week visit, Control subjects stopped the warm compress therapy and received a single Manual Mini (LipiFlow) crossover treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Manual Mini System</title>
          <description>Treatment with experimental Manual Mini System</description>
        </group>
        <group group_id="P2">
          <title>Warm Compress Therapy</title>
          <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Manual Mini System</title>
          <description>Treatment with experimental Manual Mini System</description>
        </group>
        <group group_id="B2">
          <title>Warm Compress Therapy</title>
          <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="69"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="139"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.4" spread="14.6"/>
                    <measurement group_id="B2" value="54.4" spread="16.4"/>
                    <measurement group_id="B3" value="53.4" spread="15.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Meibomian Gland Assessment (Total Meibomian Gland Secretion Score)</title>
        <description>Evaluation of secretion characteristics from the gland orifices along the lower eyelid. Assessment was based on the grading scale: 3 (clear liquid secretion), 2 (cloudy liquid secretion), 1 (inspissated), 0 (no secretion). The total meibomian gland secretion score was the sum of the grades for all 15 glands with a range of 0 to 45.</description>
        <time_frame>Baseline, 2 Weeks and 4 Weeks</time_frame>
        <population>Results presented are for the Per Protocol population. 4 Weeks data for the Warm Compress Control group are after crossover.</population>
        <group_list>
          <group group_id="O1">
            <title>Manual Mini System</title>
            <description>Treatment with experimental Manual Mini System</description>
          </group>
          <group group_id="O2">
            <title>Warm Compress Therapy</title>
            <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
          </group>
        </group_list>
        <measure>
          <title>Meibomian Gland Assessment (Total Meibomian Gland Secretion Score)</title>
          <description>Evaluation of secretion characteristics from the gland orifices along the lower eyelid. Assessment was based on the grading scale: 3 (clear liquid secretion), 2 (cloudy liquid secretion), 1 (inspissated), 0 (no secretion). The total meibomian gland secretion score was the sum of the grades for all 15 glands with a range of 0 to 45.</description>
          <population>Results presented are for the Per Protocol population. 4 Weeks data for the Warm Compress Control group are after crossover.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=130, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="3.5"/>
                    <measurement group_id="O2" value="5.6" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Weeks (N=130, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="8.7"/>
                    <measurement group_id="O2" value="6.1" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks (N=128, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="8.7"/>
                    <measurement group_id="O2" value="11.7" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Device-related Adverse Events</title>
        <description>Number of eyes for which a device-related AE occurred</description>
        <time_frame>Baseline through 4 Weeks</time_frame>
        <population>Results presented are of the Intent to Treat Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Manual Mini System</title>
            <description>Treatment with experimental Manual Mini System</description>
          </group>
          <group group_id="O2">
            <title>Warm Compress Therapy</title>
            <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Device-related Adverse Events</title>
          <description>Number of eyes for which a device-related AE occurred</description>
          <population>Results presented are of the Intent to Treat Population.</population>
          <units>Events</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dry Eye Symptoms (Total SPEED Score)</title>
        <description>Standard Patient Evaluation of Eye Dryness questionnaire. Assessment of subjects' frequency and severity of dry eye symptoms. The total score was calculated as the sum scores for all symptoms over a range of 0 to 28. A lower total SPEED score represents less frequent and/or less severe symptoms.</description>
        <time_frame>Baseline, 2 Weeks and 4 Weeks</time_frame>
        <population>Results presented are for the Per Protocol population. 4 Weeks data for the Warm Compress Control group are after crossover.</population>
        <group_list>
          <group group_id="O1">
            <title>Manual Mini System</title>
            <description>Treatment with experimental Manual Mini System</description>
          </group>
          <group group_id="O2">
            <title>Warm Compress Therapy</title>
            <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
          </group>
        </group_list>
        <measure>
          <title>Dry Eye Symptoms (Total SPEED Score)</title>
          <description>Standard Patient Evaluation of Eye Dryness questionnaire. Assessment of subjects' frequency and severity of dry eye symptoms. The total score was calculated as the sum scores for all symptoms over a range of 0 to 28. A lower total SPEED score represents less frequent and/or less severe symptoms.</description>
          <population>Results presented are for the Per Protocol population. 4 Weeks data for the Warm Compress Control group are after crossover.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=130, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="4.8"/>
                    <measurement group_id="O2" value="14.8" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Weeks (N=130, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" spread="5.5"/>
                    <measurement group_id="O2" value="11.2" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks (N=128, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" spread="5.8"/>
                    <measurement group_id="O2" value="7.9" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Surface Staining (Corneal Staining Sum Score)</title>
        <description>Corneal staining score in five corneal regions, evaluated on a scale from 0 (none), 1 (mild), 2 (moderate) to 3 (severe). The sum of the five corneal staining scores was on a scale from 0 to 15. A lower grade indicates less corneal surface desiccation.</description>
        <time_frame>Baseline through 4 Weeks</time_frame>
        <population>Results presented are of the Intent to Treat Population. 4 Weeks data for the Control group are after treatment crossover.</population>
        <group_list>
          <group group_id="O1">
            <title>Manual Mini System</title>
            <description>Treatment with experimental Manual Mini System</description>
          </group>
          <group group_id="O2">
            <title>Warm Compress Therapy</title>
            <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Surface Staining (Corneal Staining Sum Score)</title>
          <description>Corneal staining score in five corneal regions, evaluated on a scale from 0 (none), 1 (mild), 2 (moderate) to 3 (severe). The sum of the five corneal staining scores was on a scale from 0 to 15. A lower grade indicates less corneal surface desiccation.</description>
          <population>Results presented are of the Intent to Treat Population. 4 Weeks data for the Control group are after treatment crossover.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="2.2"/>
                    <measurement group_id="O2" value="2.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.9" spread="2.0"/>
                    <measurement group_id="O2" value="2.0" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="1.7"/>
                    <measurement group_id="O2" value="1.6" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intraocular Pressure</title>
        <description>Intraocular pressure (IOP) was evaluated by Goldmann applanation tonometry. Change in IOP from Baseline was assessed to confirm safety.</description>
        <time_frame>Baseline through 4 Weeks</time_frame>
        <population>Results presented are of the Intent to Treat population. Post-Treatment results for the Control group are before crossover treatment. 4 Weeks results for the Control group are after crossover treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Manual Mini System</title>
            <description>Treatment with experimental Manual Mini System</description>
          </group>
          <group group_id="O2">
            <title>Warm Compress Therapy</title>
            <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure</title>
          <description>Intraocular pressure (IOP) was evaluated by Goldmann applanation tonometry. Change in IOP from Baseline was assessed to confirm safety.</description>
          <population>Results presented are of the Intent to Treat population. Post-Treatment results for the Control group are before crossover treatment. 4 Weeks results for the Control group are after crossover treatment.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=138, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.3" spread="3.3"/>
                    <measurement group_id="O2" value="14.0" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate Post-Treatment (N=138, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" spread="3.3"/>
                    <measurement group_id="O2" value="15.0" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks (138, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" spread="2.9"/>
                    <measurement group_id="O2" value="13.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>(LogMAR) Best Spectacle Corrected Visual Acuity</title>
        <description>Measurement of BSCVA at a distance using a logMAR chart under standard illumination. The logMAR ranged from -0.30 to 1.0. A lower logMAR value is a better visual acuity.</description>
        <time_frame>Baseline, 2 Weeks and 4 Weeks</time_frame>
        <population>Results presented are of the Intent to Treat population. 2 Weeks data for the Control group are after control treatment, but before crossover treatment. 4 Weeks data for the Control group are after crossover treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Manual Mini System</title>
            <description>Treatment with experimental Manual Mini System</description>
          </group>
          <group group_id="O2">
            <title>Warm Compress Therapy</title>
            <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
          </group>
        </group_list>
        <measure>
          <title>(LogMAR) Best Spectacle Corrected Visual Acuity</title>
          <description>Measurement of BSCVA at a distance using a logMAR chart under standard illumination. The logMAR ranged from -0.30 to 1.0. A lower logMAR value is a better visual acuity.</description>
          <population>Results presented are of the Intent to Treat population. 2 Weeks data for the Control group are after control treatment, but before crossover treatment. 4 Weeks data for the Control group are after crossover treatment.</population>
          <units>LogMAR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=138, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" spread="0.12"/>
                    <measurement group_id="O2" value="0.01" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Weeks (N=136, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.13"/>
                    <measurement group_id="O2" value="0.02" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks (N=138, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.02" spread="0.12"/>
                    <measurement group_id="O2" value="-0.01" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Discomfort Evaluation (Discomfort/Pain Score)</title>
        <description>Subject-reported numeric score reflecting low or high intensity. Scores ranged from 0 to 10, with 0 being no discomfort or pain and 10 being intolerable pain.</description>
        <time_frame>Treatment and 1 Day</time_frame>
        <population>Results presented are of the Intent to Treat population. Only the Manual Mini group underwent a 1 day assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Manual Mini System</title>
            <description>Treatment with experimental Manual Mini System</description>
          </group>
          <group group_id="O2">
            <title>Warm Compress Therapy</title>
            <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
          </group>
        </group_list>
        <measure>
          <title>Discomfort Evaluation (Discomfort/Pain Score)</title>
          <description>Subject-reported numeric score reflecting low or high intensity. Scores ranged from 0 to 10, with 0 being no discomfort or pain and 10 being intolerable pain.</description>
          <population>Results presented are of the Intent to Treat population. Only the Manual Mini group underwent a 1 day assessment.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
                <count group_id="O2" value="70"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
                <count group_id="O2" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>During Treatment (N=138, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.4"/>
                    <measurement group_id="O2" value="0.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Immediate Post-Treatment (N=138, 140)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.6"/>
                    <measurement group_id="O2" value="0.0" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Day (N=138)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.7"/>
                    <measurement group_id="O2" value="NA">The Control group was not assessed for discomfort at 1 day post-treatment. This assessment refers only to discomfort after treatment with the Manual Mini System.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tear Break-up Time</title>
        <description>Tear break-up time measured under a slit lamp biomicroscope following instillation of fluorescein dye in the eye. Time was measured in seconds with a maximum of 20. Higher tear break-up time indicates better tear film stability.</description>
        <time_frame>Baseline, 2 Weeks and 4 Weeks</time_frame>
        <population>Results presented are for the Per Protocol population. 4 Weeks data for the Warm Compress Control group are after crossover.</population>
        <group_list>
          <group group_id="O1">
            <title>Manual Mini System</title>
            <description>Treatment with experimental Manual Mini System</description>
          </group>
          <group group_id="O2">
            <title>Warm Compress Therapy</title>
            <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
          </group>
        </group_list>
        <measure>
          <title>Tear Break-up Time</title>
          <description>Tear break-up time measured under a slit lamp biomicroscope following instillation of fluorescein dye in the eye. Time was measured in seconds with a maximum of 20. Higher tear break-up time indicates better tear film stability.</description>
          <population>Results presented are for the Per Protocol population. 4 Weeks data for the Warm Compress Control group are after crossover.</population>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>Eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="130"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (N=130, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.5" spread="2.9"/>
                    <measurement group_id="O2" value="5.4" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2 Weeks (N=130, 136)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9" spread="5.0"/>
                    <measurement group_id="O2" value="5.3" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>4 Weeks (N=128, 132)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="5.5"/>
                    <measurement group_id="O2" value="6.3" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The presence of adverse events was evaluated at all study visits, including unscheduled visits.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Manual Mini System</title>
          <description>Treatment with experimental Manual Mini System</description>
        </group>
        <group group_id="E2">
          <title>Warm Compress Therapy</title>
          <description>Control group receiving warm compress therapy in first study phase and crossover Manual Mini System treatment in second study phase</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Elective Knee Surgery</sub_title>
                <description>The AE was systemic and unrelated to the device and study procedures.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Stroke</sub_title>
                <description>The AE was systemic and unrelated to the device and study procedures.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christy Stevens, OD</name_or_title>
      <organization>TearScience, Inc. (formerly Kolis Scientific)</organization>
      <phone>919-459-4815</phone>
      <email>cstevens@tearscience.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

